Mologen AG
XHAM:MGNK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mologen AG
Other Non-Cash Items
Mologen AG
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mologen AG
XHAM:MGNK
|
Other Non-Cash Items
€173k
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Other Non-Cash Items
€281.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Other Non-Cash Items
€15.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Other Non-Cash Items
€49.1m
|
CAGR 3-Years
47%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Immunic Inc
NASDAQ:IMUX
|
Other Non-Cash Items
$9.4m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
112%
|
CAGR 10-Years
9%
|
|
|
Biotest AG
XETRA:BIO
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mologen AG
Glance View
MOLOGEN AG engages in the research and clinical development of drugs in the fields of oncology and infectious diseases. The company is headquartered in Berlin, Berlin and currently employs 43 full-time employees. The firm specializes in the research and development of drugs in the fields of oncology and infectious diseases. The firm develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.
See Also
What is Mologen AG's Other Non-Cash Items?
Other Non-Cash Items
173k
EUR
Based on the financial report for Dec 31, 2018, Mologen AG's Other Non-Cash Items amounts to 173k EUR.
What is Mologen AG's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
-28%
Over the last year, the Other Non-Cash Items growth was -28%. The average annual Other Non-Cash Items growth rates for Mologen AG have been -31% over the past three years , -28% over the past five years .
